Zogenix, Inc. (NASDAQ:ZGNX) major shareholder Life Sciences Maste Perceptive bought 222,055 shares of the company’s stock in a transaction dated Friday, September 29th. The stock was bought at an average price of $32.83 per share, for a total transaction of $7,290,065.65. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Life Sciences Maste Perceptive also recently made the following trade(s):

  • On Tuesday, October 3rd, Life Sciences Maste Perceptive bought 300,000 shares of Zogenix stock. The stock was bought at an average price of $37.50 per share, for a total transaction of $11,250,000.00.

Zogenix, Inc. (NASDAQ ZGNX) opened at 39.20 on Thursday. The stock has a 50 day moving average price of $16.21 and a 200-day moving average price of $13.46. Zogenix, Inc. has a 12-month low of $7.50 and a 12-month high of $41.65. The company’s market cap is $973.77 million.

Zogenix (NASDAQ:ZGNX) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.01). The company had revenue of $7.10 million during the quarter, compared to analysts’ expectations of $3.48 million. Zogenix had a negative return on equity of 70.75% and a negative net margin of 309.76%. The business’s quarterly revenue was up 238.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.76) EPS. On average, analysts predict that Zogenix, Inc. will post ($3.66) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.dailypolitical.com/2017/10/05/life-sciences-maste-perceptive-purchases-222055-shares-of-zogenix-inc-zgnx-stock.html.

A number of research firms have recently weighed in on ZGNX. Leerink Swann restated an “outperform” rating and issued a $50.00 target price (up previously from $20.00) on shares of Zogenix in a report on Monday. ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. Stifel Nicolaus restated a “buy” rating and issued a $55.00 target price (up previously from $26.00) on shares of Zogenix in a report on Friday, September 29th. William Blair upgraded Zogenix from a “market perform” rating to an “outperform” rating in a report on Friday, September 29th. Finally, Mizuho restated a “buy” rating and issued a $51.00 target price (up previously from $28.00) on shares of Zogenix in a report on Friday, September 29th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $40.00.

Several institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC grew its stake in shares of Zogenix by 192.6% in the 1st quarter. Perceptive Advisors LLC now owns 2,203,302 shares of the company’s stock worth $23,906,000 after buying an additional 1,450,303 shares during the last quarter. Kennedy Capital Management Inc. grew its stake in shares of Zogenix by 44.9% in the 1st quarter. Kennedy Capital Management Inc. now owns 1,052,990 shares of the company’s stock worth $11,425,000 after buying an additional 326,196 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Zogenix by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 974,948 shares of the company’s stock worth $10,578,000 after buying an additional 70,617 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Zogenix by 0.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 878,998 shares of the company’s stock worth $9,537,000 after buying an additional 5,415 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Zogenix by 13.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 464,761 shares of the company’s stock worth $6,739,000 after buying an additional 54,120 shares during the last quarter. Institutional investors own 87.21% of the company’s stock.

About Zogenix

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.